Tivic Health Systemsの空売り状況は、投資家がTivic Health Systemsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Tivic Health Systems (NASDAQ:TIVC) 株価情報, 空売り情報

Tivic Health Systems

Tivic Health Systems Inc is a health technology company focused on developing and commercializing non-invasive bioelectronic medicine. The company's platform-based technology activates the body's own healing mechanisms and can be programmed to treat various disease conditions. company's products provide a natural alternative to the standard synthetic chemical methods used by the pharmaceutical industry. ClearUP Sinus Relief, is a first commercial product of the company which is a patented handled device that uses ultra-low current electrical waves to relieve sinus pain and congestion symptoms that are prevalent in nasal allergies, sinus infections, chronic sinusitis, cold and flu and other disease conditions.

Movers

Trading Ideas

BIMI

DALN

FFIE

FGEN

GRPN

JTAI

LMND

MGNX

NUZE

PITA

PMEC

POWL

TBIO

TIVC

アドバンスト マイクロ デバイセズ社 (NASDAQ:AMD) の株は、予想を上回る第2四半期決算を受けて本日のプレマーケット取引で急騰している。

AMD株価上昇　決算を受けて

Tivic Health Systems, Inc. - Common stock

Tivic Health Systems Inc

<p>Scotiabank  analyst Robert Hope   upgrades Northland Power (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NPI#TSX">NPI</a>) from Sector Perform to Sector Outperform and raises the price target from C$25 to C$26.</p>


News

Upgrades

Price Target

Analyst Ratings

TSX:NPI

Scotiabank Upgrades Northland Power to Sector Outperform, Raises Price Target to C$26

<p>BMO Capital  analyst Jeffrey Silber   maintains KinderCare Learning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLC#NYSE">KLC</a>) with a Outperform and lowers the price target from $26 to $21.</p>


BMO Capital Maintains Outperform on KinderCare Learning, Lowers Price Target to $21

WIIM

Graphjet Technology shares are trading higher after the company disclosed in 13D filing that its Co-Founder, CEO and CFO Aiden Lee Ping Wei reported A 48.9% stake in the company.

<p>Siemens (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SIEGY#OTC">SIEGY</a>) reported quarterly earnings of $1.58 per share. This is a 6.76 percent increase over earnings of $1.48 per share from the same period last year.  The company reported $20.78 billion in sales this quarter. This is a 0.17 percent decrease over sales of $20.81 billion the same period last year.</p>


Earnings

SIEGY

Siemens Q2 Adj. EPS $1.58 Up From $1.48 YoY, Sales $20.78B Down From $20.81B YoY

<p>JMP Securities  analyst Reni Benjamin   reiterates LAVA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVTX#NASDAQ">LVTX</a>) from Market Perform to Market Perform.</p>


Reiteration

LVTX

JMP Securities Reiterates Market Perform on LAVA Therapeuticsto Market Perform

<p>Baird  analyst Jeffrey Meuler   maintains Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) with a Neutral and raises the price target from $11 to $13.</p>


SPIR

Baird Maintains Neutral on Spire Global, Raises Price Target to $13

<p>Baird  analyst Wesley Golladay   maintains Smartstop Self Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMA#NYSE">SMA</a>) with a Outperform and raises the price target from $38 to $40.</p>


Baird Maintains Outperform on Smartstop Self Storage, Raises Price Target to $40

<p>Baird  analyst Eric Coldwell   maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Neutral and raises the price target from $19 to $22.</p>


PINC

Baird Maintains Neutral on Premier, Raises Price Target to $22

<p>Baird  analyst Jonathan Komp   maintains Boot Barn Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) with a Outperform and raises the price target from $140 to $180.</p>


BOOT

Baird Maintains Outperform on Boot Barn Holdings, Raises Price Target to $180

<p>Federal Reserve Chair<strong> Jerome Powell </strong>said Thursday that the central bank is rethinking its approach to inflation and employment, signaling possible changes to the Fed's policy strategy as part of a major <a href="https://www.benzinga.com/news/econ-s">review underway in 2025.</a></p>
<p>&#8220;Participants have indicated that they thought it would be appropriate to reconsider the language around [labor market] shortfalls,&#8221; Powell said, referring to how the Fed talks about employment in its official strategy. </p>
<p>Powell also highlighted that &#8220;at our meeting last week, we had a similar take on average inflation targeting,&#8221; hinting that the policy introduced in 2020 may be revised or dropped.</p>
<h3 class="wp-block-heading">What's Changing And Why?</h3>
<p>In 2020, the Fed adopted a strategy to let inflation run slightly above 2% after years of staying too low. That policy, known as average inflation targeting, was meant to boost job growth and better support the economy in downturns.</p>
<p>But just months later, inflation surged far beyond the Fed's expectations, hitting a peak of 7.2% in 2022. The Fed had to respond aggressively, raising interest rates by 5.25 percentage points in just 16 months. Now, Powell says the economic landscape has changed and the old approach may no longer fit.</p>
<p>In April 2025, inflation measured by the Fed's preferred gauge—the personal consumption expenditures index—was down to 2.2%.</p>
<p> That's close to the Fed's goal and, Powell noted, "without the sharp increase in unemployment" that often comes with rate hikes. This success may be pushing the Fed to rethink whether it still needs the average inflation policy.</p>
<h3 class="wp-block-heading">Better Communication In Focus</h3>
<p>Powell also acknowledged that the Fed needs to do a better job explaining its outlook and the risks it sees. He said the central bank is looking at ways to improve how it communicates uncertainty around economic forecasts.</p>
<p>"Clear communication is an issue even in relatively placid times," he said. He added that in today's more volatile world—where shocks happen more often—it&#8217;s even more important to help the public understand that forecasts can change.</p>
<h3 class="wp-block-heading">What Happens Next?</h3>
<p>Powell said the Fed will finish its policy review in the coming months. The updated strategy will replace the one adopted in 2020 and is expected to shape how the Fed responds to future economic challenges.</p>
<p>While some core elements will stay—like the 2% inflation target—others, like the language around employment and inflation overshooting, may be rewritten.</p>
<p>For now, Powell made it clear that anchoring inflation expectations—keeping public confidence that prices will remain stable—is still the Fed's top priority. "We remain fully committed to the 2 percent target today," he said.</p>
<h3 class="wp-block-heading"><strong>Market Reactions: Dollar Rebounds, Yields Hover Near 5% After Powell Speech</strong></h3>
<p>Markets showed a mixed response to Powell's comments, with the U.S. dollar bouncing back while Treasury yields remained elevated and tech stocks took a breather.</p>
<p>The U.S. Dollar Index, as tracked by the <strong>Invesco DB USD Index Bullish Fund ETF </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), rose to 100.8, trimming earlier losses triggered by weaker-than-expected retail and producer price data <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45435725/tariffs-slow-retail-spending-as-producer-prices-post-sharpest-drop-since-2020">released earlier in the day.</a></p>
<p>Meanwhile, 30-year Treasury yields briefly touched the 5% threshold, reflecting market expectations that interest rates will remain elevated. Yields later eased slightly to 4.98% as investors digested Powell's remarks on the Fed's evolving policy stance.</p>
<p>Nasdaq 100 futures were flat, stabilizing after a three-day winning streak, as traders weighed the potential implications of a policy framework revision and a slower-than-expected inflation path.</p>
<p>Traders currently assign just an 8% probability of a 25-basis-point rate cut at the June FOMC meeting, according to CME FedWatch Tool data. The likelihood of easing increases further out, with markets fully pricing in a rate cut by September 2025.</p>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE:  Fed Chair Powell &#x7C; Thomas Laubach Research Conference &#x7C; May 15, 2025" width="500" height="281" src="https://www.youtube.com/embed/O9tcyZq4aGU?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45435725/tariffs-slow-retail-spending-as-producer-prices-post-sharpest-drop-since-2020"><strong>Tariffs Slow Retail Spending As Producer Prices Post Sharpest Drop Since 2020</strong></a></li>
</ul>
<p><em>Image created using artificial intelligence via Midjourney.</em></p>


Macro Economic Events

Currency ETFs

Econ #s

Economics

ETFs

PowerShares DB US Dollar Index Bullish Fund

Powell Signals Fed May Shift Inflation Strategy After 5 Years Of Economic Upheaval

<p>CN (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CNR#TSX">CNR</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNI#NYSE">CNI</a>) today announced its 2025 capital expenditures program, underscoring its commitment to growing capacity, enhancing safety, and powering sustainable growth across its North American network. CN will invest approximately $3.4 billion CAD in capital projects this year, net of customer reimbursements.</p>
<p>This year's capital program includes approximately $2.9 billion allocated to its maintenance and strategic infrastructure initiatives across Canada and the United States. Projects already underway include over 225 miles of new rail installation and approximately 8 capacity building projects in Western Canada scheduled to come online by the end of this year.</p>
<p>As part of this investment CN is also allocating over $500 million to upgrade and expand its rolling stock, reinforcing the Company's focus on providing safe, reliable, and efficient service for customers across its network.</p>


TSX:CNR

CN To Invest About C$3.4B In 2025 Capital Projects, Net Of Customer Reimbursements

<p>JMP Securities  analyst Reni Benjamin   reiterates Inhibrx Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBX#NASDAQ">INBX</a>) from Market Perform to Market Perform.</p>


INBX

JMP Securities Reiterates Market Perform on Inhibrx Biosciencesto Market Perform

Earnings Beats

Earnings Misses

KBCSY

UPDATE: KBC Group Q1 EPS $0.69, Sales $3.06B

<p>Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $2.13, with a high estimate of $3.00 and a low estimate of $1.50. This current average has decreased by 27.05% from the previous average price target of $2.92. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747317706_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of Pacific Biosciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$1.80</td>
<td>$1.80</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$2.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.00</td>
<td>$2.50</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.50</td>
<td>$1.75</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Pacific Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Pacific Biosciences compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Pacific Biosciences's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Pacific Biosciences's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PACB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Pacific Biosciences analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Pacific Biosciences</h2>
<p>Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.</p>
<h3>Unraveling the Financial Story of Pacific Biosciences</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Decline in Revenue:</strong> Over the 3M period, Pacific Biosciences faced challenges, resulting in a decline of approximately <strong>-4.27%</strong> in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Pacific Biosciences's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-1146.81%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Pacific Biosciences's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-142.44%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Pacific Biosciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-40.17%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Pacific Biosciences's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>7.63</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PACB

Where Pacific Biosciences Stands With Analysts

<p>Across the recent three months, 14 analysts have shared their insights on Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $284.57, a high estimate of $330.00, and a low estimate of $201.00. This current average reflects an increase of 2.41% from the previous average price target of $277.86. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747317697_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Rockwell Automation is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Dankert</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Hold</td>
<td>$290.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$327.00</td>
<td>$283.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$283.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Ken Newman</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$330.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$304.00</td>
<td>$258.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$315.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$271.00</td>
<td>$201.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$283.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$260.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$201.00</td>
<td>$248.00</td>
</tr>
<tr>
<td>Ken Newman</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$345.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$280.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$285.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Chris Dankert</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Hold</td>
<td>$280.00</td>
<td>$260.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Rockwell Automation. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Rockwell Automation compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Rockwell Automation's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Capture valuable insights into Rockwell Automation's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ROK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Rockwell Automation analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Rockwell Automation</h2>
<p>With roots tracing back to the early 1900s, Rockwell Automation is the successor to Rockwell International, which spun off its avionics segment in 2001. It is a pure-play industrial automation company that operates through three segments. Its largest segment by revenue, intelligent devices, sells factory floor-level devices such as motors, drives, sensors, relays, and actuators. Its software and control segment sells visualization, simulation, and human-machine interface software and control products such as programmable controllers, computers, and operator terminals. Its smallest segment, lifecycle services, offers digital consulting, engineered-to-order services, and other outsourced services such as remote monitoring, cybersecurity, and asset and plant maintenance and optimization.</p>
<h3>Breaking Down Rockwell Automation's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Challenges:</strong> Rockwell Automation's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately <strong>-5.88%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Rockwell Automation's net margin is impressive, surpassing industry averages. With a net margin of <strong>12.54%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Rockwell Automation's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>7.36%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Rockwell Automation's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>2.29%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Rockwell Automation's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.19</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Rockwell Automation Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)

<p>Shares of <strong>JD.com Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) fell 4.3% to $34.16 Thursday morning, tracking a broader decline in Chinese e-commerce stocks after <strong>Alibaba Group</strong> <a href="https://www.benzinga.com/news/earnings/25/05/45437447/alibaba-stock-slides-5-after-revenue-miss-cloud-spend-hits-free-cash-flow">reported</a> mixed fiscal fourth-quarter results. Alibaba stock slid 7% to $124.60 despite a better-than-expected earnings beat, as overall revenue disappointed investors.</p>
<p><strong>What To Know:</strong> Alibaba reported quarterly revenue of $32.58 billion, up 7% year-over-year but shy of analysts' $33.08 billion estimate. While adjusted earnings per share of $1.73 exceeded expectations, the top-line miss <a href="https://www.benzinga.com/news/earnings/25/05/45437447/alibaba-stock-slides-5-after-revenue-miss-cloud-spend-hits-free-cash-flow">raised concerns</a> about slower domestic consumption and heightened competition.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/25/05/45436747/coreweave-stock-is-volatile-thursday-whats-going-on">CoreWeave Stock Is Volatile Thursday: What&#8217;s Going On?</a></strong></p>
<p>Investors appeared to be spooked by weakness in segments like Cainiao Logistics, which saw a 12% revenue decline due to restructuring, and a modest 8% growth in China's core retail business. Although international and cloud businesses showed strong momentum, they weren't enough to offset concerns.</p>
<p>JD.com, often seen as a peer and rival to Alibaba, was pulled lower in a sympathy selloff Thursday, as investors reassessed the outlook for the broader Chinese e-commerce sector. Alibaba's report is potentially casting a shadow over near-term growth prospects, despite ongoing recovery signals in China's consumer market.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45435725/tariffs-slow-retail-spending-as-producer-prices-post-sharpest-drop-since-2020">Tariffs Slow Retail Spending As Producer Prices Post Sharpest Drop Since 2020</a></strong></p>
<h2 class="wp-block-heading">How To Buy JD Stock</h2>
<p>By now you're likely curious about how to participate in the market for JD.com &#8211; be it to purchase shares, or even attempt to bet against the company.</p>
<p>Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.</p>
<p>In the case of JD.com, which is trading at $34.16 as of publishing time, $100 would buy you 2.9 shares of stock.</p>
<p>If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a>  Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.</p>
<p>According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, JD has a 52-week high of $47.82 and a 52-week low of $24.13.</p>


JD.com Shares Are Trading Lower Thursday: What's Going On?

<p>Mastech Digital (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MHH#AMEX">MHH</a>) will release its quarterly earnings report on Friday, 2025-05-16. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Mastech Digital to report an <strong>earnings per share</strong> (EPS) of $0.10.</p>
<p>Investors in Mastech Digital are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS beat by $0.05 in the last quarter, leading to a 8.81% increase in the share price on the following day.</p>
<p>Here's a look at Mastech Digital's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.18</td>
<td>0.12</td>
<td>0.07</td>
<td>0.12</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.23</td>
<td>0.23</td>
<td>0.19</td>
<td>0.06</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>9.0%</td>
<td>-0.0%</td>
<td>-0.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747317680_0.png" alt="eps graph" /></p>
<h3>Performance of Mastech Digital Shares</h3>
<p>Shares of Mastech Digital were trading at $8.21 as of May 14. Over the last 52-week period, shares are up 0.06%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MHH/earnings"><strong>To track all earnings releases for Mastech Digital visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look Ahead: Mastech Digital's Earnings Forecast

<p>Across the recent three months, 7 analysts have shared their insights on Riskified (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Riskified, revealing an average target of $6.18, a high estimate of $7.00, and a low estimate of $4.50. Marking an increase of 4.22%, the current average surpasses the previous average price target of $5.93. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747317680_0_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A comprehensive examination of how financial experts perceive Riskified is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timothy Chiodo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$5.75</td>
<td>$5.50</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Reginald Smith</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$4.50</td>
<td>$4.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$7.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$7.00</td>
<td>$5.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Riskified. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Riskified compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Riskified's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Riskified's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RSKD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Riskified analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>About Riskified</h2>
<p>Riskified Ltd has built a next-generation eCommerce risk management platform that allows online merchants to create trusted relationships with their consumers. It generates revenue by granting merchants access to its eCommerce risk management platform and reviewing and approving eCommerce transactions for legitimacy. Its merchants include some of the ecommerce brands including Wayfair, Lastminute.com, SHEIN, and Macy's. Its merchants operate in a variety of verticals, including Payments, Money Transfer &amp; Crypto, Tickets &amp; Travel, Electronics, Home, Fashion &amp; Luxury Goods, General Retail and Food. The company derived maximum revenue from Israel.</p>
<h3>Riskified's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Riskified's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>11.26%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> Riskified's net margin excels beyond industry benchmarks, reaching <strong>-4.37%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Riskified's ROE excels beyond industry benchmarks, reaching <strong>-1.05%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Riskified's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>-0.82%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Riskified's debt-to-equity ratio is below the industry average. With a ratio of <b>0.07</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


RSKD

Breaking Down Riskified: 7 Analysts Share Their Views

<p>Investors with significant funds have taken a bearish position in Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), a development that retail traders should be aware of.</p>
<p>This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in ELV usually indicates foreknowledge of upcoming events.</p>
<p>Today, Benzinga's options scanner identified 10 options transactions for Elevance Health. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 10% being bullish and 60% bearish. Of all the options we discovered, 9 are puts, valued at $1,462,240, and there was a single call, worth $25,080.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $320.0 and $400.0 for Elevance Health, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Elevance Health's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Elevance Health's substantial trades, within a strike price spectrum from $320.0 to $400.0 over the preceding 30 days.</p>
<h3>Elevance Health Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747317678_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$44.8</td>
<td>$39.6</td>
<td>$42.3</td>
<td>$400.00</td>
<td>$461.0K</td>
<td align="right">636</td>
<td align="right">1</td>
</tr>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$29.0</td>
<td>$26.5</td>
<td>$29.0</td>
<td>$360.00</td>
<td>$290.0K</td>
<td align="right">417</td>
<td align="right">100</td>
</tr>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$27.0</td>
<td>$24.1</td>
<td>$27.0</td>
<td>$360.00</td>
<td>$270.0K</td>
<td align="right">417</td>
<td align="right">100</td>
</tr>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$27.0</td>
<td>$24.1</td>
<td>$27.0</td>
<td>$360.00</td>
<td>$270.0K</td>
<td align="right">417</td>
<td align="right">100</td>
</tr>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$18.2</td>
<td>$17.4</td>
<td>$17.4</td>
<td>$360.00</td>
<td>$38.2K</td>
<td align="right">196</td>
<td align="right">51</td>
</tr>
</tbody>
</table>
</p>
<h3>About Elevance Health</h3>
<p>Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 46 million medical members as of December 2024. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.</p>
<p>In light of the recent options history for Elevance Health, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Elevance Health</h3>
<ul>
<li>Trading volume stands at 325,891, with ELV's price down by -3.54%, positioned at $361.05.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 62 days.</li>
</ul>
<h3>Professional Analyst Ratings for Elevance Health</h3>
<p>4 market experts have recently issued ratings for this stock, with a consensus target price of $500.75.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $478.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Elevance Health, targeting a price of $522.<br />
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $485.<br />
&#x2A; An analyst from Guggenheim downgraded its action to Buy with a price target of $518. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Elevance Health options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Options

Markets

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Decoding Elevance Health's Options Activity: What's the Big Picture?

<p>A recent episode of "<a href="https://www.tiktok.com/@daveramsey/video/7501681088637455662">The Ramsey Show</a>" sparked discussion after a newlywed couple called in to ask financial expert <strong>Dave Ramsey</strong> for advice on a big decision: Should they go on a $20,000 African safari they won in a raffle—or skip it and stay on track to buy their first home?</p>
<h2 class="wp-block-heading">A Dream Trip Comes With a Price Tag</h2>
<p>The caller explained that she and her husband, who earn $275,000 annually, are debt-free and have a fully funded emergency fund. They're also planning to buy a house in about a year and are on track to save $87,000 toward a down payment.</p>
<p><strong>Don't Miss:</strong></p>
<ul class="wp-block-list">
<li><strong>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>with $1,000 you can invest at just $0.30/share!</strong></a></strong></li>
<li><strong>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel"><strong>Invest before it's too late.</strong></a></strong></li>
</ul>
<p>The couple had previously dreamed of taking a safari for their 10th wedding anniversary. But when they unexpectedly won an all-inclusive nine-day African safari hunt — valued at $20,000 — they were faced with a tempting opportunity much sooner than expected.</p>
<p>The raffle prize covers lodging, food, and a guided hunt in South Africa. However, as the caller pointed out, there are still significant out-of-pocket costs: airfare, gun rental, transportation, taxidermy, and shipping of the trophies. Altogether, the additional expenses could total between $12,000 and $15,000 — an amount not covered by their current $2,600 vacation fund.</p>
<h2 class="wp-block-heading">Ramsey: "You're in a Much Better Place Than I Thought"</h2>
<p>At first, Ramsey and his co-host <a href="https://www.benzinga.com/personal-finance/25/01/43061910/college-fund-or-brokerage-account-for-kids-schooling-ramsey-show-hosts-weigh-in-on-lawyers-sketchy-advice-for-single-mom">Dr. <strong>John Delony</strong></a> joked about the nature of the call — Delony calling it "the most Oklahoma call" he's ever taken. But once they heard the couple's financial background, Ramsey admitted he had expected a different scenario.</p>
<p><strong>Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"><strong> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</strong></a>.</strong></p>
<p>"You make $275,000, you&#8217;re out of debt, you have your emergency fund — vacations are on the table," Ramsey said. "You&#8217;re choosing between the size of your down payment or the distance of your down payment."</p>
<p>In other words, <a href="https://www.benzinga.com/news/25/05/45335414/dave-ramsey-tells-woman-whose-boyfriend-thinks-401ks-are-a-scam-dont-marry-this-guy-he-aint-worth-it-calling">Ramsey</a> explained, the couple could take the trip now and delay their home purchase by a few months. They could still hit their savings goals, just on a slightly different timeline.</p>
<h2 class="wp-block-heading">Postpone the House or Pass on the Zebra Rug?</h2>
<p>The caller was enthusiastic about the trip, including the possibility of bringing home a zebra rug as a memento. Her husband, on the other hand, had suggested skipping the expensive taxidermy and just taking pictures. Still, both were unsure whether it was financially wise to go on such a large trip before owning a home.</p>
<p><strong><em>See Also: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123"><strong><em>Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</em></strong></a></em></strong></p>
<p>Ramsey gave his personal answer: "I would go to Africa and delay my house by three months."</p>
<p>Delony agreed, adding, "Go do it right."</p>
<h2 class="wp-block-heading">A Memorable Decision</h2>
<p>Ultimately, Ramsey&#8217;s take was that this wasn't about blowing the budget or jeopardizing <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/05/45338011/90-of-women-investors-say-theyre-on-track-to-meet-their-financial-goals-survey-finds">financial goals</a>. Instead, it was about making a value-based choice: Would the experience of a once-in-a-lifetime trip be worth a short delay in homeownership?</p>
<p>For this couple, the answer might come down to how much they value the memories — and maybe that zebra rug.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></strong></li>
<li><strong>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</strong></a></strong></li>
</ul>
<p><em><strong>Image: Shutterstock</strong></em></p>


Personal Finance

Couple Wins $20K For African Safari Hunt, Asks Dave Ramsey If They Should Pay The Extra $15K To Go Or Keep Saving For A House

Press Releases

Tivic Health to Report 2024 Year-End Financial Results on March 21st Via Conference Call and Webcast

Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth

$2 Stocks to Watch: PNPN.V, TIVC, APVO, OSRH, PRSO Biotech Breakthroughs, MedTech Momentum Metallic Metals Power Play & Signal Innovation

Tivic Health Systems, Inc. Regains Compliance with NASDAQ Minimum Bid Price Listing Rule

Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia

Tivic Health Reports White House Briefing and FDA Meetings Secured Positive Interest in Potential Military and Defense Applications of Its Product Candidates

Comments

Tivic Health Systems

空売り

Tivic Health Systems (NASDAQ:TIVC) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル